NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Feb 27, 2026
- Closes
- Dec 1, 2030 (in 1499 days)
Similar opportunities open now
- Translational Neural Devices (R61/R33 - Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2027
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028Up to $499K
- Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2027
- Focused Technology Research and Development (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Apr 2027
Classification and identifiers
- Solicitation number
- RFA-EB-28-004
- Assistance listing (CFDA)
- 93.273
Amount
Amount not listed here. Check the official program.
Who can apply
Private colleges and universities, Small businesses, and Local government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
This Notice of Funding Opportunity (NOFO) is to encourage applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) and The Helping to End Addiction Long-term (HEAL) Initiatives. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.